1. pregnant or lactating 2. treatment with covid-19 antiviral such as remdesivir or sars-cov-2 antibodies 3. at increased risk of developing more severe covid-19 disease (at least one of the following): 1. age ≥60 years 2. presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema 3. diabetes mellitus (type 1 or 2), requiring oral medication or insulin for treatment 4. cardiovascular disease, including hypertension, requiring at least 1 oral medication for treatment; congestive heart failure; coronary artery disease; cardiomyopathy; pulmonary hypertension 5. body mass index ≥30 6. chronic renal disease (but not on dialysis) 7. sickle cell disease or trait 4. severe or critical covid-19, as indicated by respiratory distress or shortness of breath at rest; resp rate ≥30/min; heart rate ≥125/min; spo2 ≤ 93% on room air or pao2/fio2 ≤ 300 if on supplemental o2 5. positive hiv or positive hepatitis panel 6. treatment with any medications known to be strongly metabolized by cyp3a4 or cyp2d6

1. pregnant or lactating 2. treatment with covid-19 antiviral such as remdesivir or sars-cov-2 antibodies 3. at increased risk of developing more severe covid-19 disease (at least one of the following): 1. age ≥60 years 2. presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema 3. diabetes mellitus (type 1 or 2), requiring oral medication or insulin for treatment 4. cardiovascular disease, including hypertension, requiring at least 1 oral medication for treatment; congestive heart failure; coronary artery disease; cardiomyopathy; pulmonary hypertension 5. body mass index ≥30 6. chronic renal disease (but not on dialysis) 7. sickle cell disease or trait 4. severe or critical covid-19, as indicated by respiratory distress or shortness of breath at rest; resp rate ≥30/min; heart rate ≥125/min; spo2 ≤ 93% on room air or pao2/fio2 ≤ 300 if on supplemental o2 5. positive hiv or positive hepatitis panel 6. treatment with any medications known to be strongly metabolized by cyp3a4 or cyp2d6

pregnant or lactating treatment with covid-19 antiviral such as remdesivir or sars-cov-2 antibodies at increased risk of developing more severe covid-19 disease (at least one of the following): age ≥60 years presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema diabetes mellitus (type 1 or 2), requiring oral medication or insulin for treatment cardiovascular disease, including hypertension, requiring at least 1 oral medication for treatment; congestive heart failure; coronary artery disease; cardiomyopathy; pulmonary hypertension body mass index ≥30 chronic renal disease (but not on dialysis) sickle cell disease or trait severe or critical covid-19, as indicated by respiratory distress or shortness of breath at rest; resp rate ≥30/min; heart rate ≥125/min; spo2 ≤ 93% on room air or pao2/fio2 ≤ 300 if on supplemental o2 positive hiv or positive hepatitis panel treatment with any medications known to be strongly metabolized by cyp3a4 or cyp2d6

pregnant or lactating treatment with covid-19 antiviral such as remdesivir or sars-cov-2 antibodies at increased risk of developing more severe covid-19 disease (at least one of the following): age ≥60 years presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema diabetes mellitus (type 1 or 2), requiring oral medication or insulin for treatment cardiovascular disease, including hypertension, requiring at least 1 oral medication for treatment; congestive heart failure; coronary artery disease; cardiomyopathy; pulmonary hypertension body mass index ≥30 chronic renal disease (but not on dialysis) sickle cell disease or trait severe or critical covid-19, as indicated by respiratory distress or shortness of breath at rest; resp rate ≥30/min; heart rate ≥125/min; spo2 ≤ 93% on room air or pao2/fio2 ≤ 300 if on supplemental o2 positive hiv or positive hepatitis panel treatment with any medications known to be strongly metabolized by cyp3a4 or cyp2d6

pregnant or lactating treatment with covid-19 antiviral such as remdesivir or sars-cov-2 antibodies prior covid-19 vaccination or prior recovery from documented covid-19 infection severe or critical covid-19, as indicated by respiratory distress or shortness of breath at rest; resp rate ≥30/min; heart rate ≥125/min; spo2 ≤ 93% on room air or pao2/fio2 ≤ 300 if on supplemental o2 positive hiv or positive hepatitis panel treatment with any medications known to be strongly metabolized by cyp3a4 or cyp2d6

pregnant or lactating treatment with covid-19 antiviral such as remdesivir or sars-cov-2 antibodies prior covid-19 vaccination or prior recovery from documented covid-19 infection severe or critical covid-19, as indicated by respiratory distress or shortness of breath at rest; resp rate ≥30/min; heart rate ≥125/min; spo2 ≤ 93% on room air or pao2/fio2 ≤ 300 if on supplemental o2 positive hiv or positive hepatitis panel treatment with any medications known to be strongly metabolized by cyp3a4 or cyp2d6

1. pregnant or lactating 2. treatment with covid-19 antiviral such as remdesivir or sars-cov-2 antibodies 3. prior covid-19 vaccination or prior recovery from documented covid-19 infection 4. severe or critical covid-19, as indicated by respiratory distress or shortness of breath at rest; resp rate ≥30/min; heart rate ≥125/min; spo2 ≤ 93% on room air or pao2/fio2 ≤ 300 if on supplemental o2 5. positive hiv or positive hepatitis panel 6. treatment with any medications known to be strongly metabolized by cyp3a4 or cyp2d6

1. pregnant or lactating 2. treatment with covid-19 antiviral such as remdesivir or sars-cov-2 antibodies 3. prior covid-19 vaccination or prior recovery from documented covid-19 infection 4. severe or critical covid-19, as indicated by respiratory distress or shortness of breath at rest; resp rate ≥30/min; heart rate ≥125/min; spo2 ≤ 93% on room air or pao2/fio2 ≤ 300 if on supplemental o2 5. positive hiv or positive hepatitis panel 6. treatment with any medications known to be strongly metabolized by cyp3a4 or cyp2d6